Aravive Biologics

August 9, 2019September 10, 2019

AVB-500 Plus Chemotherapy More Effective Than Chemo Alone in Platinum-resistant Patients, Early Trial Data Suggest

News

Aravive‘s experimental treatment, AVB-500, in combination with chemotherapy appears to be more effective than chemotherapy alone at treating platinum-resistant ovarian cancer, preliminary results from a first group of patients taking ... Read more

January 21, 2019

Phase 1b/2 Trial of AVB-S6-500 for Platinum-resistant Recurrent OC Begins

News

The first part of a Phase 1b/2 trial evaluating the combination of Aravive Biologics’ investigational therapy AVB-S6-500 with standard-of-care therapies in patients with platinum-resistant recurrent ovarian cancer has begun treating ... Read more

August 22, 2018August 22, 2018

Aravive Biologics’ Therapy Earns FDA’s Fast Track Designation to Treat Advanced Ovarian Cancer

News

The U.S. Food and Drug Administration (FDA) has granted fast track designation to AVB-S6-500 as a potential therapy for chemotherapy-resistant ovarian cancer, Aravive Biologics, the therapy’s developer, announced. Fast track designation is given ... Read more